Tetrazole derivatives
US-2024382468-A2 · Nov 21, 2024 · US
Compounds and methods for inhibiting JAK
US9714236B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9714236-B2 |
| Application number | US-201615272554-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 22, 2016 |
| Priority date | Sep 25, 2015 |
| Publication date | Jul 25, 2017 |
| Grant date | Jul 25, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R 1 is methyl or ethyl; R 2 is selected from methyl, ethyl, methoxy and ethoxy; R 3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R 4 is selected from methyl, ethyl and —CH 2 OCH 3 ; R 5 and R 6 are each individually methyl or hydrogen; and R 7 is selected from methyl, ethyl, —(CH 2 ) 2 OH and —(CH 2 ) 2 OCH 3 , or a pharmaceutically acceptable salt thereof.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound which is (2R)—N-(3-{2-[(3-methoxy-1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-1H-indol-7-yl)-2-(4-methylpiperazin-1-yl)propanamide, or a pharmaceutically acceptable salt thereof. 2. The compound of claim 1 , which is (2R)—N-(3-{2-[(3-methoxy-1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-1H-indol-7-yl)-2-(4-methylpiperazin-1-yl)propanamide. 3. The compound of claim 1 , which is a pharmaceutically acceptable salt of (2R)—N-(3-{2-[(3-methoxy-1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-1H-indol-7-yl)-2-(4-methylpiperazin-1-yl)propanamide. 4. A solid form of (2R)—N-(3-{2-[(3-methoxy-1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-1H-indol-7-yl)-2-(4-methylpiperazin-1-yl)propanamide, or a pharmaceutically acceptable salt thereof. 5. A pharmaceutical composition comprising a compound of any one of claims 1 - 3 , and a pharmaceutically acceptable diluent, excipient or carrier.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Drugs for disorders of the blood or the extracellular fluid · CPC title
Immunomodulators · CPC title
Antineoplastic agents · CPC title
- C07D403/14Primary
containing three or more hetero rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9714236B2 cover?
- Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R 1 is methyl or ethyl; R 2 is selected from methyl, ethyl, methoxy and ethoxy; R 3 is selected from hydrogen, …
- Who is the assignee on this patent?
- Astrazeneca Ab
- What technology area does this patent fall under?
- Primary CPC classification C07D403/14. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 25 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).